These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23018916)

  • 41. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid.
    Chen Q; Huang T; Zou L; Tang X; Shi Z; Wang X; Wu H; Sun J; Lu X; Liang L; Jiang L; Liu D; Tang S; Wu G; He W
    Sci Rep; 2024 Jul; 14(1):17347. PubMed ID: 39069547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
    [No Abstract]   [Full Text] [Related]  

  • 43. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
    Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.
    Wells CD; Gupta R; Hittel N; Geiter LJ
    Eur Respir J; 2015 May; 45(5):1498-501. PubMed ID: 25700385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR; Marathe PA
    J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
    Dhakulkar S; Das M; Sutar N; Oswal V; Shah D; Ravi S; Vengurlekar D; Chavan V; Rebello L; Meneguim AC; Iyer A; Mansoor H; Kalon S; Acharya S; Ferlazzo G; Isaakidis P; Thakur HP
    PLoS One; 2021; 16(2):e0246639. PubMed ID: 33600431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Undergraduate Medical Teaching: Time to integrate?
    Ravikirti ; Sharma S
    J Assoc Physicians India; 2018 Aug; 66(8):85-86. PubMed ID: 31324092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
    Holmgaard FB; Guglielmetti L; Lillebaek T; Andersen ÅB; Wejse C; Dahl VN
    Clin Infect Dis; 2023 Apr; 76(7):1328-1337. PubMed ID: 36331978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
    Solodovnikova V; Kumar AMV; Hurevich H; Sereda Y; Auchynka V; Katovich D; Klimuk D; Skrahin A; Setkina S; Charnysh I; Yedilbayev A; Skrahina A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
    Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
    Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 54. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Chang KC; Leung EC; Law WS; Leung WM; Tai LB; Lee SN; Lam FM; Chau CH; Mok TY; Yew WW; Leung CC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29650556
    [No Abstract]   [Full Text] [Related]  

  • 55. Novel drugs against tuberculosis: a clinician's perspective.
    Olaru ID; von Groote-Bidlingmaier F; Heyckendorf J; Yew WW; Lange C; Chang KC
    Eur Respir J; 2015 Apr; 45(4):1119-31. PubMed ID: 25431273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
    N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
    [No Abstract]   [Full Text] [Related]  

  • 59. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
    Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
    Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL].
    Okumura M; Yoshiyama T
    Kekkaku; 2016 Nov; 91(11-12):699-702. PubMed ID: 30648372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.